Monopar Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock Incentive Plan (Tables)

Stock Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2023

Stock Incentive Plan

Stock Option Activity

		Options Outstanding
		Number of Shares Subject to Options				Weighted-Average Exercise Price
Balances at December 31, 2022			1,642,950				4.28
Granted⁽¹⁾			508,902				3.14
Forfeited⁽²⁾			(5,729	)			2.44
Balances at March 31, 2023			2,146,123				4.01
Unvested options outstanding expected to vest⁽³⁾			901,308				3.45

Options Outstanding

Exercise Prices		Number of Shares Subject to Options Outstanding				Weighted-Average Remaining Contractual Term in Years				Number of Shares Subject to Options Fully Vested and Exercisable				Weighted-Average Remaining Contractual Term in Years
$0.001-$5.00			1,397,112				7.73				600,616				5.38
$5.01-$10.00			629,216				6.14				528,988				5.78
$10.01-$15.00			113,670				6.81				109,086				6.80
$15.01-$20.00			6,125				6.84				6,125				6.84
			2,146,123				7.21				1,244,815				5.68

Restricted Stock Unit Activity

		Restricted Stock Units (#)				Weighted- Average Grant Date Fair Value per Unit ($)
Unvested balance at December 31, 2022			272,650				4.00
Granted			368,345				3.16
Vested			(41,202	)			5.35
Unvested Balance at March 31, 2023			599,793				3.39

Schedule Of Stock Option Grants And Fair Values

		Three Months Ended March 31,
		2023				2022

Stock options granted			508,902				553,064
Weighted-average grant date fair value per share		$	2.38				2.11
Fair value of shares vested		$	223,273				292,328